Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118202 · ClinicalTrials.gov registry record · NA
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
A NA study of Hepatocellular Carcinoma Recurrent, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 198
- Enrollment target
- 6
- Study locations
NCT07118202: Recruiting NA study of Hepatocellular Carcinoma Recurrent, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT07118202 is a NA study of Hepatocellular Carcinoma Recurrent that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 198 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07118202, a NA study of Hepatocellular Carcinoma Recurrent, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 198 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Primary Outcome
Overall survival assessment will be recorded in days and will represent the period starting at the date of treatment initiation and finishing at the date of patient death from any cause. Living patients at the time of analysis will have the date of last contact (consultation visit or phone contact) used to define overall survival
Conditions Studied
Interventions
- DEVICE TheraBionic P1
Study Locations (6)
Michigan
- Karmanos Cancer Institute at McLaren Bay Region - Bay City
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute at McLaren Flint - Flint
- Karmanos Cancer Institute at McLaren Greater Lansing - Lansing
- Karmanos Cancer Institute at McLaren Lapeer Region - Lapeer
- Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center - Mount Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT07118202 shows while recruiting
NCT07118202 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Hepatocellular Carcinoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which TheraBionic P1 is the first listed.
NCT07118202 lists 6 locations in 1 state (Michigan).
Frequently Asked Questions
What is clinical trial NCT07118202 about?
NCT07118202 is a clinical study titled "TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma". The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall surviv...
What is the current status of trial NCT07118202?
This trial is currently recruiting. It is a NA study. The enrollment target is 198 participants. The study started on 2025-10-20. Estimated completion is 2027-08-31.
What conditions does trial NCT07118202 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma Recurrent.
What interventions are being tested in trial NCT07118202?
The interventions under investigation include: TheraBionic P1 (DEVICE).
Who is sponsoring clinical trial NCT07118202?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07118202 being conducted?
This trial has 6 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07118202's enrollment target sits among peer trials
198 567th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI